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physicians and 55% for residents physicians. Similarly the accuracy was higher in
the ambulatory setting than for inpatient, 89% vs. 62%. The yield for the HTN group
was also higher with attendings than residents, 100% vs. 67%, and the yield was
higher in ambulatory versus inpatient settings, 87% vs. 64%. CONCLUSIONS: CDS
based onmedication orders during CPOEmay improve problem lists. The accuracy
and yield of diagnostic information is sensitive to medication type, clinical venue
and possibly clinician type. Mandatory indication based prescribing may not pro-
duce very accurate indication data. There is a substantial need for further research
in this area.
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OBJECTIVES: Treatment strategies for atrial fibrillation (AF) are classified into rate
control and rhythm control. They can be employed through the use of pharmaco-
logical and non-pharmacological approaches. This study described the trend in the
utilization of treatment strategies for the management of AF in newly diagnosed
patients between 1999 and 2008.METHODS: The study was a retrospective cohort
study of administrative claims data from a large nationally dispersed group of
commercially insured subjects from 1999-2008. Newly diagnosed AF patients aged
18 years and with at least one claim for an AF related intervention within 12
months of diagnosis were identified. Based on initial treatment received, patients
were classified in pharmacotherapy or non-pharmacotherapy treatment groups.
Patients initiated on drug-therapies were classified into rate-control (beta-blocker,
calcium channel blocker or digoxin) or rhythm control groups. Descriptive analysis
was conducted to compare the patient demographic characteristics across the
treatment groups. OLS regressionwas conducted to assess linear trends. RESULTS:
Of the 6284 newly diagnosed AF patients who received treatment within one-year,
83.7% underwent pharmacotherapy as the 1st line therapy. Majority (86.3%) of pa-
tients who initiated drug therapy received rate-control medications only. Relative
distribution of different treatments across timedid not vary significantly. However,
within rate-control group, beta-blockers use increased significantly (p 0.0001)
from 47.5% (1999) to 70.58% (2008), whereas use of calcium channel blockers and
digoxin decreased. Non-pharmacotherapy was employed more commonly in the
mid-west (44.95%, p0.0002), in patients younger than 65 years (58.35%, p0.0001)
and its use decreased with increasing age. Males were more likely to undergo
non-pharmacotherapy (69.9%, p 0.0001). CONCLUSIONS: Higher utilization of
rate control as 1st line therapy compared to other treatment strategies is consistent
with the current literature. Greater use of non-pharmacotherapy in younger pa-
tients can be partially explained by the higher success rate in this population.
PCV97
IS CARDIOVASCULAR MEDICATION USAGE A MARKER FOR CARDIOVASCULAR
RISK? POTENTIAL IMPLICATION FOR SMART-EDIT FORMULARY MANAGEMENT
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BACKGROUND: In the current statin landscape, a need has emerged for simple and
less data-intensive tools to identify patients at risk for cardiovascular events and to
appropriately identify patients for higher-efficacy statin use. OBJECTIVES: To ex-
amine the feasibility of a pharmacy-based algorithm as amarker of cardiovascular
risk to guide appropriate statin selection at the point of service. METHODS: A
retrospective analysis using an integrated database of over 70 pooled health plans
was conducted for the period 2003 to mid-2010. Patients on at least one cardiovas-
cular medication of interest (N 4,276,418) and18 years old werematched by age
and gender to control subjects (not on cardiovascular medications [N 3,046,021]).
Cardiovascular medications included were antihypertensive, antidiabetic, anti-
anginal, antiarrhythmic, anticoagulant, non-statin lipid modifier, and antiplatelet
drugs. Subjects’ cardiovascular risk status (high/moderate/low) was assessed ac-
cording to the current National Cholesterol Education Program guidelines, from
records of diagnoses and procedures. Relative risks were calculated for the likeli-
hood of being at increased risk (high or moderate risk status) as the ratio of pro-
portions of patients on cardiovascular medication versus controls who were at
increased risk. RESULTS: The study population had amean age of 53 years. Overall,
a patient receiving any cardiovascularmedicationwas 2.4 timesmore likely to be at
increased risk (95%CI 2.39,2.40) and was 2.7 times more likely to experience a car-
diovascular event (95%CI 2.73,2.74) than a subject not receiving any cardiovascular
medication. Additionally, it was observed that 27% of the total patients in the
health plans who were on cardiovascular medications accounted for 71.5% of all
cardiovascular events in that group. CONCLUSIONS: A pharmacy algorithm based
on usage of various cardiovascular medications can be used to identify increased
cardiovascular risk. These initial findings demonstrate the potential of using
widely available cardiovascular prescription data in designing statin formulary
management strategies.
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OBJECTIVES: Electronicmedical records (EMRs) increasingly are being used by out-
comes researchers to study the quality of medical care. The study assessed the
impact of non-medical switches in ARB therapy on blood pressure (BP) andmedical
resource utilization including office visits and other antihypertensivemedications.
METHODS: A retrospective study was conducted using the GE Centricity EMR of a
primary care physicians group. Hypertensive patients18 years, continuously en-
rolled, and receiving ARB therapy were included. Switch must have occurred after
the patient was on the first ARB for at least 60 days. The control group remained on
the sameARBanddid not switch. A 1:1matchingwas done on the duration of initial
ARB therapy and presence of diabetes or renal impairment. Demographic charac-
teristics, clinical parameters, ARB use, and office visits were identified. Data was
extracted using Microsoft SQL and statistical analyses were conducted using SPSS
version 18.0. RESULTS: A total of 4,851 patients (mean age 68.23 years, female
58.1%) were prescribed an ARB between 2004 and 2008 out of which 3,083 (63.6%)
stayed on one ARB and 1,768 (36.4%) switched from one ARB to another. Matched
pairs of switchers (n357) and control group (n357) were then identified. There
was no difference in mean baseline systolic BP (SBP) for switchers (143.7921.22)
and control (144.2022.16) but switchers had higher post-switch SBP
(141.0618.52) than control (137.9720.58) (p0.035). More switchers lost control
from index to first visit post-index period (11.5%) than control (8.7%). More antihy-
pertensive agents were added in switchers (1.911.7) than control (1.021.2) in the
post-index period (p0.001). CONCLUSIONS: EMRs have the potential to bridge
research with clinical care by providing real-world data. This study demonstrates
that non-medical switches may result in loss of BP control and additional medical
resource use. Thus, careful consideration should be given before switching thera-
pies for non-medical reasons.
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OBJECTIVES: The study objective was to determine medical resource utilization
and direct and indirect costs following hospitalization with chronic heart failure
(HF). METHODS: Patients with 1 hospitalization with a chronic HF claim (ICD-9
428.22, 428.32 or 428.42) were identified in a US commercial insurance claims da-
tabase from 2004-2008. Patients were observed from beginning of first hospitaliza-
tion (index hospitalization) for chronic HF until disenrollment or end of data avail-
ability. Inpatient, outpatient, and prescription drug data were used to estimate per
patient per month (PPPM) utilization rates. Costs (2009 USD) were calculated per
hospitalization and PPPM for patients65 years, and included insurers’ reimburse-
ment, patient out-of-pocket and sick leave costs. RESULTS: There were 7,814 pa-
tients (mean age 73.2 years, 55.7% male) meeting inclusion criteria. Mean HF hos-
pitalization length of stay increased from 6.7 days at index hospitalization to 8.2
days at fourth re-hospitalization. Rate of HF-related re-hospitalization remained
over 0.045 PPPM throughout 24 months of follow-up, accounting for over 78% of
all-cause hospitalizations. Rate of all-cause and HF-related outpatient visits
peaked at 4.0 and 0.59 visits PPPM, respectively, within the three months after
index hospitalization. Index hospitalization was most expensive (direct medical
costs$31,998). Patient out-of-pocket costs accounted for less than 10% of direct
hospitalization costs and sick leave costs were less than $1,800 at any hospitaliza-
tion. During the study period, outpatient cardiovascular drugs accounted for a
small proportion of total pharmacy costs (approximately 20%); average PPPM cost
varied from $88 to $124, representing less than 1% of the average cost of a HF-
related hospitalization. CONCLUSIONS: Treating chronic HF patients is resource
intensive. The greatest utilization and cost burden occur within the three months
after index hospitalization and patients continue to be burdened after hospitaliza-
tion by high inpatient and outpatient visit rates.
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OBJECTIVES: 1) To determine costs and utilization incurred by employees follow-
ing enrollment in an employer-sponsoredmedication therapymanagement (MTM)
program and 2) to assess the impact of attrition on health care expenditures.
METHODS: A longitudinal study using medical claims. Study participants were
Lucas County employees with diabetes, hypertension and/or hyperlipidemia par-
ticipating in an employer-sponsored open-enrollment MTM program. Claims for
office, emergency roomand inpatient visitswere analyzed for the period of January
2005-July 2010. Disease-related expenditures were tracked for a period of two-year
pre- and post enrollment. All expenditures were calculated as average costs per-
patient pre and post joining and also as total expenditure borne by the employer.
Dropouts were identified from an appointment database. Expenditures were cal-
culated using claims for one year before and after the dropout date. RESULTS:
Claims were received for 361 employees that enrolled in the MTM program. Office
visit expenses went down by $71,442.29 or by 22.36% after joining the MTM pro-
gram. An increase in spending for emergency room visits by $12,597.16 was ob-
served, there were no recurring post-enrollment visits and those that occurred
were for indications that could have increased long-term spending for the em-
ployer. Total expenditure on inpatient visits went up by approximately $7600 but
the amount spent on each visit went down from $7,746.36  4,169.13 to 4,408.07 
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6,204.77.Number of employees who had an inpatient visit increased from 3 to 7,
with no recurrence of pre-visit events. A decrease in total health care expenditures
by over 14%was observed. Preliminary analysis for the second objective shows that
on average employees spent $406.97/patient/year more when they dropped out of
the program than if they stayed enrolled. CONCLUSIONS: Pharmacist led MTM-
program helped reduce health care expenditure for the employer. Improving re-
tention for the program could help substantiate these cost savings.
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OBJECTIVES: To identify existing gender differences in utilization of preventive
care services in the United States (US) population using a national database. Few
studies have pointed towards role of gender in determining utilization of preven-
tive care service but the issue hasn’t been explored using a nationally representa-
tive population.METHODS:A retrospective, cross-sectional study using 2008MEPS
(Medical Expenditure Panel Survey) data, a nationally representative survey of US
population, which reports their pattern of medical care utilization. Guideline rec-
ommendations widely used in clinical practice, such as NCEP, American Dental
Society, JNC-VII etc., were used to determine appropriate utilization of preventive
care services. Descriptive statistics were used to describe the population charac-
teristics while multivariate logistic regression model was built to predict the utili-
zation of the various preventive care services (blood pressure check up, lipid
screening, dental check up, sigmoidoscopy/colonoscopy andflu vaccination), using
gender as the primary predictor variable, while controlling for age, income, race/
ethnicity etc. RESULTS:Out of 33,066 respondents, 20,336met the inclusion criteria
for blood pressure check up, 23,058 met the inclusion criteria for dental check up,
19,543 met the inclusion criteria for flu vaccinations, 2,986 met the inclusion crite-
ria for lipid screening, and 4,195 met the inclusion criteria for sigmoidoscopy/
colonoscopy screenings. Gender was found to predict utilization of preventive care
services.Maleswere found less likely to utilize blood pressure check up (OR 0.327,
CI 0.2970.359), lipid screening (OR 0.768, CI0.694- 0.85), dental check up (OR
0.634,CI  0.599-0.671), and flu vaccination (OR  0.680, CI 0.637- 0.726). In case of
sigmoidoscopy and colonoscopy screenings, the disparities were not significant,
though utilization was still found to be higher in females. CONCLUSIONS: The study
helped determine gender disparities in utilizing preventive care services in US
population. Utilization of preventive care services needs to be encouraged inmales.
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OBJECTIVES: Limited data exist regarding the economic burden of complications
arising during stroke-related hospitalizations. This study sought to document the
rate of complications arising during hospitalization (i.e., defined as diagnoses re-
corded upon discharge but not observed at admission) for hemorrhagic (HS) or
ischemic stroke (IS), and describe characteristics of complicated hospitalizations.
METHODS: Data for hospitalizations with a primary diagnosis of HS (ICD-9-CM
codes 430.xx, 431.xx, or 432.xx) or IS (433.x1, 434.xx, or 436.xx) in the 2008 HCUP
Michigan State Inpatient Database were analyzed. Incidence of complications de-
veloped during hospitalization among patientswith a primary diagnosis of HS or IS
were assessed, and resource-based outcomes (e.g., total cost, length of stay [LOS])
among, and other characteristics of, stays with complications, compared to un-
complicated hospitalizations, analyzed. RESULTS: Of the 1.3 million hospitaliza-
tions occurring in Michigan in 2008, 19,065 had a primary diagnosis of HS or IS.
Among these, 20.6% (n3,922) had evidence of1 complications arising during the
stay. No differences in patient age (mean: 70.4 versus 70.7 years; p0.3293) or
gender distribution (53% versus 54% female; p0.3476) between complicated and
uncomplicated hospitalizations were observed. The top-5 most frequently ob-
served complications were urinary tract infection, site not specified; hypopotasse-
mia; acute respiratory failure; pneumonitis due to inhalation of food or vomitus;
and acute kidney failure, unspecified. Compared to uncomplicated hospitaliza-
tions, mean LOS and total costs for complicated stays were significantly greater:
10.5 versus 4.5 days (p0.0001) and $28,608 versus $10,747 (p0.0001), respectively.
Patients with 1 complications spent 2.8 (SD6.4) days in an ICU, and a greater
proportion with complications than without died during hospitalization (11.4%
versus 6.6%; p0.0001). CONCLUSIONS: The cost of stroke-related hospitalizations
with complications is significant,3 times greater than stroke-related hospitaliza-
tions without complications. Efforts to improve inpatient stroke management
strategies may help lower the incidence of complications, reduce associated costs,
and improve patient outcomes.
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OBJECTIVES: The patient-centered medical home has been touted as a way to
improve patient care and reduce overall healthcare costs. Pharmacists are qualified
to provide many of the services that are core to the medical home concept as part
of the physician-directed team; however, the pharmacist’s role in the medical
home has received little attention. METHODS: Medical record review was per-
formed on all patients referred to the pharmacist from 7/1/2009 to 12/1/2010within
a community-based, medical home, primary care practice. Patients referred in-
cluded those non-compliant to prior physician recommendations for lifestyle
modifications and/or those not achieving therapeutic goals. Pharmacist interven-
tions included disease state education, therapeutic lifestylemodification andmed-
ication counseling, and recommendations for therapy optimization. Primary anal-
yses examined pre/post changes in the subset of patients with diabetes. Outcomes
assessed were changes in hemoglobin A1c (HbA1c), lipid fractions, body mass in-
dex (BMI), weight, and goal attainment for HbA1c and low-density lipoprotein cho-
lesterol (LDL-C), utilizing paired t-tests, Wilcoxon signed-rank and McNemar’s
tests as appropriate. RESULTS: One hundred-seven patients were referred to the
pharmacist, 49 with diabetes. Diabetes patients had amean age of 579 years; 53%
weremale. HbA1c values decreased from 8.7% to 7.4% (	1.3%; 95% CI0.5% to
2.1%; p0.003). The percentage of patients achieving HbA1c levels below 8% rose
from 50% to 75% (p0.021) and below 7% rose from 28% to 47%, although this was
not statistically significant (p0.109). Statistically significant decreases were ob-
served in diastolic blood pressure, LDL-C, total cholesterol, triglycerides, BMI and
weight. The percentage of patients achieving LDL-C levels 100mg/dL increased
from 30% to 74% (p0.002). CONCLUSIONS: Pharmacist involvement in this com-
munity basedmedical homewas associatedwith positive improvements in clinical
markers for these diabetic patients. These pilot study results support the inclusion
of pharmacists as healthcare team members in future medical home demonstra-
tion projects.
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OBJECTIVES: To compare side effect data reported from members of a patient-
registry to information contained in the product labeling of four different choles-
terol medications each representing a different therapeutic class. METHODS: A
random sample of U.S. MediGuard.org members who reported taking niacin (Nias-
pan), fenofibrate (Tricor), simvastatin (Zocor), or colesevelam (Welchol), were in-
vited to complete a validated online treatment satisfaction survey that includes
questions related to side effects. MediGuard.org is a free medication monitoring
service that provides information to over 2.5 million members in the US, UK,
France, Germany, Spain, and Australia. A comparison list of adverse effects and
frequencies reported during clinical trials was extracted from the branded package
insert for each medication. RESULTS: Feedback was obtained from 56 colesvelam,
108 niacin, 216 fenofibrate, and 660 simvastatin patients. Niacin patients had the
highest prevalence of side effects (62%), primarily flushing (55%) and pruritis (14%).
23% of colesevelam members reported side effects: the most common were con-
stipation (14%) and bloating/gas (2%). For patients treated with fenofibrate, 16%
reported side effects withmyalgia (4.2%) and arthralgia (1.4%) being themost com-
mon. Similar to fenofibrate, 16% of simvastatin patients reported side effects and
again, myalgia (6.2%) and fatigue (2.1%) had the most mentions. Finally, 2% of
niacin, 22% of fenofibrate, 29% of simvastatin, and 36% of colesevelam patient
reports included side effects not included in the product labeling. CONCLUSIONS:
On-line patient communities are an emerging resource for confirming adverse
events reported during clinical trials and for capturing previously undocumented
signals. In tandem to the current post-marketing spontaneous adverse event re-
porting system, longitudinal patient registries can provide insight not only on the
number of adverse events, but also a prevalence rate of those who experience
versus those who do not experience side effects.
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OBJECTIVES: The objectives of this audit are: (1) to determine the percentage of
patients who are discharged on secondary prevention medication following acute
myocardial infarction (AMI) including: aspirin, clopidogrel, ACE inhibitors (ACEi),
-blockers (BB), and statins; (2) to identify what dose each patient is discharged on
regarding ACEi and BB and when they are initiated; (3) to explore the relationship
between blood pressure and ACEi dose titration; (4) to explore the relationship
between heart rate and BB dose titration.METHODS: A prospective audit was car-
ried out at the London Chest Hospital (LCH) from June 15-June 28, 2009. All patients
who were admitted to the coronary care unit (CCU) with a final diagnosis of AMI
were included. Patients were excluded if they died prior to hospital discharge.
Patients’ demographics, vital signs, drug history, past medical history, drugs dur-
ing hospital stay and at discharge were collected. RESULTS: 33 patients were in-
cluded in this audit (mean age 59.7  12.7 years, 79% males, 21% females) with an
average length of stay of 2.2 days. 88% of the patients were started ACEi and BB on
day 2 of hospitalization. For patients receiving ACEi and BB only 41% were titrated
towards the optimal dose. 78% of the opportunities to titrate ACEi according to
blood pressure and 55% of the opportunities to titrate BB according to heart rate
were not taken. At discharge, 100% were prescribed aspirin, statins, and BB; while
97% were prescribed ACEi and clopidogrel. CONCLUSIONS: This audit reveals high
use of secondary prevention medication at the LCH following AMI. Although there
are opportunities for further dose titration prior to discharge, further work is re-
quired to establish reasons for missing these opportunities.
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